Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3751
Alto Neuroscience
ANRO
$1.13B
| $541K | ﹤0.01% |
30,392
+30,350
| +72,262% | +$382K |
|
3752
Entravision Communication
EVC
$832M
| $540K | ﹤0.01% |
184,463
+13,814
| +8% | +$35.9K |
|
3753
Greif Class B
GEF.B
$4.24B
| $540K | ﹤0.01% |
7,231
+685
| +10% | +$45.5K |
|
3754
Beyond Meat
BYND
$214M
| $539K | ﹤0.01% |
657,254
+354,414
| +117% | +$493K |
|
|
BMNR
3755
BitMine Immersion Technologies
BMNR
$10.8B
| $538K | ﹤0.01% |
19,822
-89,956
| -82% | -$3.65M |
|
3756
Rocket Pharmaceuticals
RCKT
$374M
| $537K | ﹤0.01% |
153,049
+3,656
| +2% | +$12.5K |
|
3757
Owlet
OWLT
$169M
| $537K | ﹤0.01% |
33,180
+30,777
| +1,281% | +$349K |
|
3758
CALL
Corteva
CTVA
$50.4B
| $536K | ﹤0.01% |
8,000
+4,000
| +100% | +$259K |
|
3759
Ginkgo Bioworks
DNA
$486M
| $536K | ﹤0.01% |
64,465
+6,665
| +12% | +$71.8K |
|
3760
Fractyl Health
GUTS
$111M
| $535K | ﹤0.01% |
+243,294
| New | +$392K |
|
3761
PUT
ASP Isotopes
ASPI
$541M
| $535K | ﹤0.01% |
100,000
| – | – |
|
3762
Babcock & Wilcox
BW
$1.46B
| $533K | ﹤0.01% |
84,118
+84,017
| +83,185% | +$414K |
|
3763
NewtekOne
NEWT
$370M
| $531K | ﹤0.01% |
46,818
+3,638
| +8% | +$39.7K |
|
3764
B&G Foods
BGS
$291M
| $531K | ﹤0.01% |
123,460
+6,451
| +6% | +$28.8K |
|
3765
MainStreet Bancshares
MNSB
$177M
| $530K | ﹤0.01% |
26,048
+3,707
| +17% | +$72.5K |
|
3766
BV Financial
BVFL
$180M
| $530K | ﹤0.01% |
29,203
+781
| +3% | +$13.4K |
|
3767
E.W. Scripps
SSP
$314M
| $529K | ﹤0.01% |
132,533
-48,415
| -27% | -$163K |
|
3768
Lightbridge
LTBR
$333M
| $528K | ﹤0.01% |
41,791
+11,549
| +38% | +$222K |
|
3769
Stoneridge
SRI
$197M
| $528K | ﹤0.01% |
91,207
+34,905
| +62% | +$220K |
|
3770
ArcelorMittal
MT
$55.9B
| $526K | ﹤0.01% |
11,542
+11,365
| +6,421% | +$467K |
|
3771
Orion
OEC
$364M
| $526K | ﹤0.01% |
99,612
+13,858
| +16% | +$75.2K |
|
3772
CALL
Genius Sports
GENI
$2.12B
| $525K | ﹤0.01% |
+47,600
| New | +$519K |
|
3773
Abeona Therapeutics
ABEO
$425M
| $523K | ﹤0.01% |
99,311
+37,014
| +59% | +$186K |
|
3774
Woodside Energy
WDS
$43.6B
| $522K | ﹤0.01% |
+33,456
| New | +$532K |
|
3775
RBB Bancorp
RBB
$462M
| $519K | ﹤0.01% |
25,157
+1,067
| +4% | +$21K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.